Learn more →
Back to Expert Scholars
Immunotherapy / 免疫治疗Cancer Immunology

Sergio A. Quezada

塞尔希奥·克萨达

PhD

🏢University College London Cancer Institute(伦敦大学学院癌症研究所)🌐UK

Professor of Tumour Immunology; Head, Immune Regulation and Tumour Immunotherapy Lab肿瘤免疫学教授;免疫调节与肿瘤免疫治疗实验室主任

58
h-index
2
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Sergio Quezada at UCL is a leading European cancer immunologist specializing in regulatory T cells and checkpoint biology. His mechanistic work on how Tregs and CTLA-4 enforce tumor immune escape, and how anti-CTLA-4 depletes intratumoral Tregs via ADCC, has provided critical insights into checkpoint immunotherapy mechanisms and resistance.

Share:

🧪Research Fields 研究领域

Regulatory T Cells调节性T细胞
FOXP3 BiologyFOXP3生物学
CTLA-4 Mechanism of ActionCTLA-4作用机制
Tumor Immune Escape肿瘤免疫逃逸
Combination Immunotherapy联合免疫治疗

🎓Key Contributions 主要贡献

CTLA-4 Blockade Depletes Intratumoral Tregs

Demonstrated that anti-CTLA-4 (ipilimumab) exerts anti-tumor activity partly by depleting FOXP3+ Tregs within the tumor microenvironment via Fc-mediated ADCC, explaining differential efficacy and informing next-generation antibody engineering.

Treg Functional States in Tumor Immune Escape

Characterized distinct functional states and transcriptional programs of tumor-infiltrating Tregs, showing how highly activated Tregs suppress effector T cells and create an immunosuppressive niche that promotes tumor escape.

Combination CTLA-4 and PD-1 Synergy Mechanisms

Elucidated mechanistic basis for synergy between CTLA-4 and PD-1 blockade in preclinical models, linking Treg depletion with relief of T cell exhaustion and informing clinical combination checkpoint strategies.

Representative Works 代表性著作

[1]

CTLA-4 control over Foxp3+ regulatory T cell function

Science (2011)

Showed that CTLA-4 on Tregs is required for their suppressive capacity and that anti-CTLA-4 antibodies deplete tumor-infiltrating Tregs, linking CTLA-4 biology directly to immunotherapy mechanism.

[2]

Intratumoral Foxp3+ regulatory T cells and anti-CTLA-4 treatment

Journal of Clinical Investigation (2006)

Seminal study showing that anti-CTLA-4 antibody treatment reduces intratumoral Tregs and that Treg depletion is a key component of ipilimumab efficacy in solid tumors.

🏆Awards & Recognition 奖项与荣誉

🏆Cancer Research UK Future Leaders in Cancer Research Prize
🏆European Research Council Consolidator Grant
🏆BBSRC David Phillips Fellowship
🏆UCL Cancer Institute Distinguished Scientist Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 塞尔希奥·克萨达 的研究动态

Follow Sergio A. Quezada's research updates

留下邮箱,当我们发布与 Sergio A. Quezada(University College London Cancer Institute)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment